Walmart (WMT) traded down -1.02 % during a 24 hours period ending at 07:19 PM Central Europe on Monday 26th. One Walmart stock can currently be bought for about USD 119.72 on popular exchanges. Current supply of Walmart stocks is 7.9 bn. Walmart has a current market capitalization of USD 951.2 bn and approximately USD 2.2 bn worth of Walmart was traded on exchanges in the last 24 hours. Since last month end, Walmart has traded 11.43 % up. Simple moving average of last 200 days is at USD 118.42. The highest price of past 52 weeks was recorded at USD 135.16 on 05/19/2026. 52 weeks low was at USD 98.88 on 11/14/2025.
Summary of the latest news for Walmart
Walmart Inc. has introduced new rules governing the use of AI agents for purchasing, with the terms taking effect immediately on October 25. The company is rolling out the related Agent Profiles and Agent Gateway in phases, initially available to corporate and developer beta users. The guidelines restrict agents from accessing payment card details or altering payment methods, require customer approval for purchases, and impose spending limits. Standard return procedures apply, and non‑compliant agents will be blocked. Walmart’s platform now supports conversational shopping through integrations such as Muse, ChatGPT, and Gemini, offering a controlled environment that mirrors human price visibility. Early pilot data suggest that transactions initiated by agents convert at roughly one‑third the rate of standard click‑throughs.
Here is how related stocks have performed in the past 24 hours:
Micron (MU) traded up 2.46 % and now trades at USD 914.24. Micron has a market capitalisation of USD 992.9 bn. Current price/earnings ratio for Micron is 11.82. Micron Technology Inc. has seen its stock trade within a narrow range during the day, reflecting a steady but modest performance amid broader market volatility. The semiconductor company’s shares remained largely stable, with limited movement that suggests investors are monitoring ongoing supply‑chain dynamics and the company’s recent product developments. No significant corporate announcements or earnings releases were reported in the period covered, and the broader sector has experienced mixed results, with some memory‑chip peers posting gains while others see modest declines. The overall market context includes continued interest in AI‑related hardware, but the immediate impact on Micron’s valuation appears neutral.
Jpmorgan Chase & (JPM) traded down -1.47 % and now trades at USD 335.09. Jpmorgan Chase & has a market capitalisation of USD 880.5 bn. Jpmorgan Chase & has a current price to earnings ratio of 13.96. JPMorgan Chase & Co. announced that its private‑bank division is deploying artificial‑intelligence tools to improve client onboarding and research workflows, aiming to enhance adviser productivity across its Europe, Middle East and Africa operations. The firm plans a 10–15 % increase in adviser headcount over the next few years, while maintaining hiring momentum in other regions. The initiative is part of a broader strategy to combine technology‑driven efficiency with continued expansion of its wealth‑management services, as the bank seeks to attract younger clients and adapt to evolving market conditions.
Palantir (PLTR) traded up 0.29 % and now trades at USD 199.49. Palantir has a market capitalisation of USD 472.8 bn. Current price/earnings ratio for Palantir is 167.28. Palantir Technologies Inc. has highlighted the potential of artificial intelligence to broaden employment opportunities for neurodivergent individuals. The company’s CEO, Alex Karp, has spoken about how AI can level the playing field by allowing different cognitive styles to be better valued in the workplace. In line with this perspective, Palantir offers a neurodivergent fellowship that recruits people who think differently, emphasizing skills such as pattern recognition and deep focus that are considered advantageous in an AI‑driven environment. The programme underscores the firm’s commitment to inclusive hiring and the belief that diverse thinking can enhance the company’s work. No other corporate developments or market movements for Palantir were mentioned in the available reports.
Mastercard (MA) traded down -1.52 % and now trades at USD 614.37. Current market capitalisation for Mastercard is USD 546.3 bn. Current price/earnings ratio for Mastercard is 34.21. Mastercard Inc. reported its earnings for the quarter, noting continued investment in artificial‑intelligence initiatives while acknowledging cash outflows that surpassed inflows. The company also announced a two‑for‑one share split and the issuance of non‑voting shares to support further expansion. These developments come amid a broader earnings season that includes other major technology names such as Amazon, Microsoft, and Alphabet. Investors are also watching the Federal Reserve’s upcoming policy decision, as market participants assess the potential impact of interest‑rate levels on consumer spending and corporate investment. The overall market environment remains volatile, with recent oil price movements adding additional pressure to equity valuations, while bond yields have shown signs of a re‑emerging hedge function. Mastercard’s financial update reflects a cautious approach to growth investments amid uncertain macro‑economic conditions.
Eli Lilly & (LLY) traded down -2.54 % and now trades at USD 1,281.82. Current market capitalisation for Eli Lilly & is USD 1.1 trillions. Eli Lilly & has a current price to earnings ratio of 42.58. Eli Lilly announced new first‑line data for its investigational KRAS G12C inhibitor, olomorasib, at the 2026 ESMO Congress. Results from a phase 1/2 study and the safety‑lead‑in portion of a phase 3 trial showed durable activity when combined with the PD‑1 inhibitor pembrolizumab, with neither median progression‑free survival nor response duration reached after roughly 21 months of follow‑up. In a separate single‑arm analysis of olomorasib plus chemo‑immunotherapy, the investigator‑assessed overall response rate was about 62 %, with a median response duration around 14½ months and a median progression‑free survival near 11½ months. Adverse events were manageable, with no fatal treatment‑related events reported. Lilly expects the first randomized phase 3 SUNRAY‑01 results in the first half of 2027, which will further evaluate olomorasib in combination with immunotherapy, with or without chemotherapy, across all PD‑L1 expression levels.
About Walmart
Walmart Inc. is a discount store chain that offers a wide range of merchandise including apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddlers, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. The company serves customers worldwide and can be accessed through its website at www.walmart.com . Walmart is listed on the New York Stock Exchange.
